Pathologic Stage III Esophageal Adenocarcinoma AJCC v8

general

Stage IIIB includes: (T2, N2, M0, Any G); (T3, N1-2, M0, Any G); (T4a, N0-1, M0, Any G). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)

6

Centers

8

Active Trials

—

Cancer Funding

Top Centers for Pathologic Stage III Esophageal Adenocarcinoma AJCC v8(6)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH
NCI Comprehensive
High-Volume Research Center
73.3
2
City of Hope Comprehensive Cancer CenterDuarte, CA
NCI Comprehensive
High-Volume Research Center
73.3
3
Memorial Sloan Kettering Cancer CenterNew York, NY
NCI Comprehensive
Active Research Program
50.8
4
Moffitt Cancer CenterTampa, FL
NCI Comprehensive
Active Research Program
50.8
5
University of Illinois Cancer CenterChicago, IL
Active Research Program
50.8
6
Boston University Cancer CenterBoston, MA
Active Research Program
50.8

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →